First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors

Sponsor:

Bicara Therapeutics

Sponsor Study ID:

BCA101X1101

CTO #:

103341

NCT Number:

NCT04429542

Phase:

I

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Anus; Bladder; Breast; Cervix Uteri; Colon; Corpus Uteri; Esophagus; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid

Study Objectives:

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)